Navigation Links
Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma

CHICAGO and REGENSBURG - June 21, 2007 - “In anaplastic astrocytoma, AP 12009 as a monotherapy is actually clearly superior to temozolomide,” Prof. Albert Wong, M.D., Stanford University, California, U.S.A. commented on the international Phase IIb study with the TGF-beta 2-inhibitor AP 12009, under development by Antisense Pharma. Prof. Wong discussed the results of the study in the poster discussion session on central nervous system tumors at the 43rd Annual Meeting of the American Society of Clincal Oncology (ASCO) in Chicago, USA, this month.

The Phase IIb study AP 12009-G004 is an open-label, randomized, actively-controlled, parallel-group dose-finding study to evaluate the efficacy and safety of two doses of AP 12009 in adult patients with recurrent high-grade glioma. Efficacy endpoints were tumor response assessed by central blinded MRI reading and survival. At 29 international clinical centers 134 evaluable patients (39 with anaplastic astrocytoma, AA, WHO grade III and 95 with glioblastoma, GBM, WHO grade IV) have been randomized to three arms: AP 12009 10 ?M, AP 12009 80 ?M and chemotherapy (Temozolomide or PCV) as a control. AP 12009 was administered intratumorally via one catheter as continuous high-flow microperfusion over a 7-day period every other week for up to 6 months on an outpatient treatment basis (1, 2). Post-study follow-up for survival, long-term tumor response, and safety is still ongoing. Analysis of the core phase for AA patients is completed.

Tumor response was assessed according to Macdonald criteria. The response rate for AP 12009 10 ?M in anaplastic astrocytoma patients steadily increased in the course of 14 months, whereas in the chemotherapy treatment arm a transient peak of the response rate at 6 months was not sustainable and decreased to zero at 14 months. Response rates were higher in the AP 12009 10 ?M group compared to the AP 12009 80 ?M group. The
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Lorus Therapeutics Announces Scientific Presentations for Lead Antisense and siRNA Drug Candidates at International Cancer Conference
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014  Unilife Corporation ("Unilife" ... announced today that it intends to release its financial ... ended June 30, 2014 after market trading ends on ... scheduled a conference call for 4:30 p.m. U.S. EDT ... at 6:30 a.m. AEST), to review the Company,s financial results, ...
(Date:8/29/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... that results in demyelination, axonal transection, and neurodegeneration. The ... by the immune system, which targets neurons within the ... disease in which the damage of the myelin sheath ...
(Date:8/29/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... consumables to the medical, research and veterinary markets, announced ... Executive Officer, will present at the CL King 12 ... September 9, 2014 at 12:30 p.m. ET. The conference ... in New York City . ...
Breaking Medicine Technology:Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
... 24 Sunridge International (OTC Bulletin Board: SNDZ ... month to have meetings with key brokers and funds.  The ... our company,s technology, and to facilitate funding for Sunridge to ... is a good time for this project," states G. Richard ...
... Corporation (Nasdaq: CLSN ), a leading ... U.S. Food and Drug Administration (FDA) has designated ... in combination with radiofrequency ablation (RFA), as a ... liposomal encapsulation of doxorubicin, is currently being evaluated ...
Cached Medicine Technology:Celsion Receives Fast Track Designation for ThermoDox® Development Program to Treat Primary Liver Cancer 2Celsion Receives Fast Track Designation for ThermoDox® Development Program to Treat Primary Liver Cancer 3Celsion Receives Fast Track Designation for ThermoDox® Development Program to Treat Primary Liver Cancer 4
(Date:8/29/2014)... USA (PRWEB) August 29, 2014 As reported ... Is Help (8/15), the process of admitting that you ... a struggle. The article acknowledges and highlights the fact that ... problem, you may be very overwhelmed by all of the ... is nearly impossible to sift through, it is still possible ...
(Date:8/29/2014)... Market Research Report on Global and ... and in-depth market survey on Global and Chinese ... basic information of Glass microfiber including its classification, ... global and China’s top manufacturers of Glass microfiber ... market share etc. , The report further analyzes ...
(Date:8/29/2014)... A recent article discusses the creation ... clothing store for men with gynecomastia, or male breasts, to ... their problem. Board-certified plastic surgeon Dr. Chasan is familiar with ... people only associate male breasts with men who are excessively ... of all ages, often starting in adolescence. Men with the ...
(Date:8/29/2014)... IL (PRWEB) August 29, 2014 Pursuing ... is set to unveil a stunning new design ... to company figures, the highly notable surrogacy platform has ... January. With over 13,000 visitors a month, the FindSurrogateMother.com ... mothers working toward one common goal — the precious ...
(Date:8/29/2014)... report released yesterday by the Mental Health Commission ... health training and education that police personnel receive. ... issue for Canada,s police community, and today,s report ... enforcement and people with mental illnesses," says Queen,s ... an interest in the area of police psychology. ...
Breaking Medicine News(10 mins):Health News:What to Know When Seeking Drug Addiction Help 2Health News:What to Know When Seeking Drug Addiction Help 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 2Health News:New Bra Created for Men with Gynecomastia, But Will It Work? 3Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Report advocates improved police training 2
... ... Michael Steele join Tea Party Support ( http://teapartysupport.com ) and the ... do whatever is necessary, including the use of any parliamentary device ... its tracks. ,Rush Limbaugh questioned Senate Minority Leader McConnell’s strategy ...
... , SAN DIEGO, Dec. 11 ... of post-secondary education services focused on providing higher access to ... graduate school specializing in psychology programs at the master,s and ... in Career Management and Counseling. , This specialization responds ...
... NEW YORK, Dec. 11 WebMD Health Corp. (Nasdaq: ... offer to purchase up to 5,700,000 shares of its common ... at 5:00 p.m., New York City time on December 10, ... Transfer & Trust Company, the Depositary for the tender offer, ...
... December 11 2009 (Portland, Ore.) More than 10 ... at risk for developing diabetes during pregnancy, according to a ... in the December issue of the Ethnicity and Disease ... women,s gestational diabetes risk is one-third higher than averageand more ...
... , ... Board legally recovers the books and records of U.S. Shanghai Chemical Corporation from Chinese Principals! ... (PRWEB) December 11, 2009 ... Axxexs Capital, Inc. was acquired by a Chinese chemical company in a reverse merger. Principals ...
... ... ... do not believe that they know much about depression , but are highly aware of ... National Alliance on Mental Illness (NAMI)., , ,See full survey results at http://www.nami.org/depression , ...
Cached Medicine News:Health News:Rush Limbaugh & Michael Steele Join Tea Party Support & Social Security Institute-Demand GOP Senate Stop ObamaCare by Any Means Possible 2Health News:Rush Limbaugh & Michael Steele Join Tea Party Support & Social Security Institute-Demand GOP Senate Stop ObamaCare by Any Means Possible 3Health News:Bridgepoint Education's University of the Rockies Introduces New Master of Arts Specialization in Career Management and Counseling 2Health News:WebMD Health Corp. Announces Preliminary Results of Its Tender Offer 2Health News:WebMD Health Corp. Announces Preliminary Results of Its Tender Offer 3Health News:Chinese-American and Korean-American women at highest risk for diabetes in pregnancy 2Health News:Chinese-American and Korean-American women at highest risk for diabetes in pregnancy 3Health News:New Board Gains Control of U.S. Shanghai Chemical Corporation 2Health News:Depression Survey: Implications for Diverse Communities 2Health News:Depression Survey: Implications for Diverse Communities 3
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish....
Oval solid 16 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Cross action serrated handle with polished finish....
Oval solid 15 mm wide lower plate. Open upper plate with inside dimensions 11 mm x 8 mm. Serrated handle with locking thumb screw and polished finish....
Slender 4.5 mm long rounded platform. Serrated handle with polished finish....
Medicine Products: